Recent News

• 03.31.2026 - New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
• 03.30.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 03.26.2026 - Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
• 03.09.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 02.26.2026 - Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
• 02.24.2026 - Definium Therapeutics to Participate at Upcoming Investor Conferences
• 02.19.2026 - Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Recent Filings

• 03.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2026 - 144 Report of proposed sale of securities
• 03.25.2026 - 144 Report of proposed sale of securities
• 03.25.2026 - 144 Report of proposed sale of securities
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - 8-K Current report
• 02.26.2026 - EX-99.1 EX-99.1
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors